NLRP3 and gout: Colchicine, that has been the drug of choice for gout attack for more than 200 years, that blocks MSU crystal-induced IL-1β generation upstream of NLRP3 inflammasome activation possibly by suppressing the microtubule-mediated NLRP3 inflammasome assembly (55, 56).